222 related articles for article (PubMed ID: 7191289)
41. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
[TBL] [Abstract][Full Text] [Related]
42. Synthesis of thrombin-inhibiting heparin mimetics without side effects.
Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371
[TBL] [Abstract][Full Text] [Related]
43. [Control of the therapeutic heparin dosage in platelet rich citrate plasma after protamine neutralization].
Görss EW; Maercker W
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):815-22. PubMed ID: 2436996
[TBL] [Abstract][Full Text] [Related]
44. From heparin to heparin fractions and derivatives.
Coyne E
Semin Thromb Hemost; 1985 Jan; 11(1):10-2. PubMed ID: 3883496
[No Abstract] [Full Text] [Related]
45. Differential anticoagulant activity of heparin fragments prepared using microbial heparinase.
Linhardt RJ; Grant A; Cooney CL; Langer R
J Biol Chem; 1982 Jul; 257(13):7310-3. PubMed ID: 7085627
[TBL] [Abstract][Full Text] [Related]
46. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
Chang LC; Lee HF; Chung MJ; Yang VC
Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
[TBL] [Abstract][Full Text] [Related]
47. The monitoring of heparin activity during extracorporeal circulation.
Gomperts ED; Bethlehem B; Hockley J
S Afr Med J; 1977 Jun; 51(26):973-6. PubMed ID: 888033
[TBL] [Abstract][Full Text] [Related]
48. [New antithrombotic oligosaccharides].
Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
Ann Pharm Fr; 1999 May; 57(3):232-9. PubMed ID: 10427858
[TBL] [Abstract][Full Text] [Related]
49. Anticoagulant activity of a bacterial glycopeptide.
Akoum A; Josefonvicz J; Sigot M
Thromb Res; 1990 Oct; 60(1):9-18. PubMed ID: 2126150
[TBL] [Abstract][Full Text] [Related]
50. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
51. Role of heparin in the inactivation of thrombin, factor Xa, and plasmin by antithrombin III.
Stürzebecher J; Markwardt F
Thromb Res; 1977 Dec; 11(6):835-46. PubMed ID: 146278
[No Abstract] [Full Text] [Related]
52. A facile colorimetric protamine titration method.
Teng CL; Yang VC
J Lab Clin Med; 1989 Apr; 113(4):498-504. PubMed ID: 2467958
[TBL] [Abstract][Full Text] [Related]
53. Multiple functional domains of the heparin molecule.
Oosta GM; Gardner WT; Beeler DL; Rosenberg RD
Proc Natl Acad Sci U S A; 1981 Feb; 78(2):829-33. PubMed ID: 6940150
[TBL] [Abstract][Full Text] [Related]
54. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
55. Antithrombin activity of surface-bound heparin studied under flow conditions.
Lindhout T; Blezer R; Schoen P; Willems GM; Fouache B; Verhoeven M; Hendriks M; Cahalan L; Cahalan PT
J Biomed Mater Res; 1995 Oct; 29(10):1255-66. PubMed ID: 8557728
[TBL] [Abstract][Full Text] [Related]
56. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
Elgue G; Blombäck M; Olsson P; Riesenfeld J
Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
[TBL] [Abstract][Full Text] [Related]
57. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
58. The effect of platelet factor 4 (PF4) on assays of plasma heparin.
Levine SP; Sorenson RR; Harris MA; Knieriem LK
Br J Haematol; 1984 Aug; 57(4):585-96. PubMed ID: 6743573
[TBL] [Abstract][Full Text] [Related]
59. Antifactor Xa activity measured with amidolytic methods.
Odegård OR; Lie M; Abildgaard U
Haemostasis; 1976; 5(5):265-75. PubMed ID: 1017722
[TBL] [Abstract][Full Text] [Related]
60. [From heparin to synthetic antithrombotic oligosaccharides].
Petitou M
Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
